循环脂肪因子水平与川崎病的关系研究-现代医学

循环脂肪因子水平与川崎病的关系研究

单位：1. 商洛市商州区人民医院儿科, 陕西商洛 726000;
2. 商洛市中心医院儿科, 陕西商洛 726000;
3. 西安市儿童医院新生儿科, 陕西西安 710003

分类号：R725.4

出版年·卷·期（页码）：2019·47·第八期（913-919）

摘要：

目的：探索循环脂肪因子水平与急性期川崎病间的关系。方法：对2015-2017年于我院经确诊并收治的共124例急性期川崎病患儿采集外周血液标本，并应用酶联免疫实验（ELISA）的方法检测病理组织中趋化素、网膜素-1、脂联素、TNF-α及IL-1β含量，并比较其在川崎病例、一般性发热及健康儿童间的差异。结果：病例组血清趋化素水平（81.27±56.82）显著高于健康对照组（42.57±11.07）及发热对照组（61.08±21.64）（P<0.05）；病例组血清网膜素-1（376.71±123.30）显著低于发热对照组（551.37±202.25）；病例组血清脂联素水平（14.97±6.34）明显低于发热对照组（33.82±11.48）；川崎病组IL-1β的血清细胞因子水平（13.65±3.15）高于正常对照组（2.49±0.35）（P<0.05）。结论：血清中脂肪因子的变化与急性川崎病的早期炎症和脂质代谢紊乱密切相关。

Objective:To investigate the relationship between adipokines including chemerin, omentin-1, adiponectin and acute Kawasaki disease. Methods:Enzyme-linked immunosorbent (ELISA) was used to detect serum levels of chemerin, omentin-1, adiponectin, and inflammatory cytokines IL-1β and TNF-α in 124 cases of patients diagnosed with Kawasaki disease (KD). In addition, 56 cases of children with fever and 61 cases of healthy children were selected as febrile and normal controls. Results:Serum levels of chemerin in KD group (81.27±56.82) were higher than that of both the healthy (42.57±11.07) and the febrile controls (61.08±21.64) (P<0.05); Circulating omentin-1 levels in Kawasaki disease group (376.71±123.30) were significantly lower than that of febrile control (551.37±202.25) (P<0.05), also serum adiponectin levels in Kawasaki disease group (14.97±6.34) reduced obviously compared with the febrile control group (33.82±11.48). Serum cytokine levels of IL-1β in Kawasaki disease group (13.65±3.15) were higher than those of normal controls (2.49±0.35) (P<0.05). Conclusion:These adipokines are closely associated with the early inflammation and lipid metabolism disorders of acute Kawasaki disease.

参考文献：

[1] KAWASAKI T.Acute febrile mucocutaneous syndrome with lymphoid involvement with specific desquamation of the fingers and toes in children[J].Arerugi,1967,16(3):178-222.
[2] 江彦秋,黄先玫.川崎病的免疫与遗传学发病机制研究进展[J].中华实用儿科临床杂志,2017(9):717-720.
[3] NEWBURGER J W,TAKAHASHI M,GERBER M A,et al.Diagnosis,treatment,and long-term management of Kawasaki disease:a statement for health professionals from the committee on rheumatic fever,endocarditis,and kawasaki disease,council on cardiovascular disease in the young,American heart association[J].Pediatrics,2004,114(6):1708-1733.
[4] 高燕,赵璐,刘芳,等.川崎病合并冠状动脉病变[J].中国小儿急救医学,2014(6):393-395.
[5] LIANG C D,KUO H C,YANG K D,et al.Coronary artery fistula associated with Kawasaki disease[J].Am Heart J,2009,157(3):584-588.
[6] 徐雯雅,刘桂英.川崎病合并冠状动脉损害危险因素研究进展[J].中国医药,2016,11(2):293-297.
[7] 梁秋月,刘晓燕.川崎病冠状动脉血栓形成发病机制及治疗进展[J].国际儿科学杂志,2016,43(3):213-216.
[8] 朱丹颖.川崎病冠状动脉损害易患基因研究进展[J].国际儿科学杂志,2017,44(5):297-300.
[9] 赵峥山.川崎病冠状动脉病变的遗传学研究进展[J].国际儿科学杂志,2018,45(5):329-332.
[10] CAO H.Adipocytokines in obesity and metabolic disease[J].J Endocrinol,2014,220 (2):T47-T59.
[11] CARBONE F,MACH F,MONTECUCCOF.The role of adipocytokines in atherogenesis and atheroprogression[J].Curr Drug Targets,2015,16(4):295-320.
[12] OUCHI N,HIGUCHI A,OHASHI K,et al.Sfrp5 is an anti-inflammatory adipokine that modulates metabolic dysfunction in obesity[J].Science,2010,329(5990):454-457.
[13] KEMMOTSU Y,SAJI T,KUSUNOKI N,et al.Serum adipokine profiles in Kawasaki disease[J].Mod Rheumatol,2012,22(1):66-72.
[14] KIM H J,CHOI E H,KIL H R.Association between adipokines and coronary artery lesions in children with Kawasaki Disease[J].J Korean Med Sci,2014,29(10):1385-1390.
[15] MCCRINDLE B W,ROWLEY A H,NEWBURGER J W,et al.Diagnosis,treatment,and long-term management of Kawasaki disease:A scientific statement for health professionals from the American heart association[J].Circulation,2017,135(17):e927-e999.
[16] 刘宁.川崎病的治疗进展[J].医药导报,2016,35(2):157-161.
[17] BOZAOGLU K,BOLTON K,McMILLAN J,et al.Chemerin is a novel adipokine associated with obesity and metabolic syndrome[J].Endocrinology,2007,148(10):4687-4694.
[18] ZABEL B A,ZUNIGA L,OHYAMA T,et al.Chemoattractants,extracellular proteases,and the integrated host defense response[J].Exp Hematol,2006,34(8):1021-1032.
[19] PAROLINI S,SANTORO A,MARCENARO E,et al.The role of chemerin in the colocalization of NK and dendritic cell subsets into inflamed tissues[J].Blood,2007,109(9):3625-3632.
[20] LANDGRAF K,FRIEBE D,ULLRICH T,et al.Chemerin as a mediator between obesity and vascular inflammation in children[J].J Clin Endocrinol Metab,2012,97(4):E556-E564.
[21] GU P,JIANG W,LU B,et al.Chemerin is associated with inflammatory markers and metabolic syndrome phenotypes in hypertension patients[J].Clin Exp Hypertens,2014,36(5):326-332.
[22] ERDOGAN S,YILMAZ F M,YAZICI O,et al.Inflammation and chemerin in colorectal cancer[J].Tumour Biol,2016,37(5):6337-6342.
[23] DESSEIN P H,TSANG L,WOODIWISS A J,et al.Circulating concentrations of the novel adipokine chemerin are associated with cardiovascular disease risk in rheumatoid arthritis[J].J Rheumatol,2014,41(9):1746-1754.
[24] SENOLT L,POLANSKA M,FILKOVA M,et al.Vaspin and omentin:new adipokines differentially regulated at the site of inflammation in rheumatoid arthritis[J].Ann Rheum Dis,2010,69(7):1410-1411.
[25] MENZEL J,DI GIUSEPPE R,BIEMANN R,et al.Association between chemerin,omentin-1 and risk of heart failure in the population-based EPIC-Potsdam study[J].Sci Rep,2017,7(1):14171.
[26] OHASHI K,SHIBATA R,MUROHARA T,et al.Role of anti-inflammatory adipokines in obesity-related diseases[J].Trends Endocrinol Metab,2014,25(7):348-355.
[27] NIGRO E,SCUDIERO O,MONACO M L,et al.New insight into adiponectin role in obesity and obesity-related diseases[J].Biomed Res Int,2014,2014:658913.
[28] SHIBATA S,TADA Y,HAU C,et al.Adiponectin as an anti-inflammatory factor in the pathogenesis of psoriasis:induction of elevated serum adiponectin levels following therapy[J].Br J Dermatol,2011,164(3):667-670.
[29] LEE Y,SCHULTE D J,SHIMADA K,et al.Interleukin-1beta is crucial for the induction of coronary artery inflammation in a mouse model of Kawasaki disease[J].Circulation,2012,125(12):1542-1550.

服务与反馈：

【文章下载】【发表评论】【查看评论】【加入收藏】

提示：您还未登录，请登录！点此登录